Madrigal Pharmaceuticals Inc (MDGL) Stock Price & News

MDGL:NASDAQ

Madrigal Pharmaceuticals Inc

$541.08

-0.28%

(-1.53) 1D

$541.08

0.00% (0.00)

After hours

Closed: Sep 4, 4:00:01 PM GMT-4 · USD

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for MDGL...

Open

$536.82

High

$547.92

Low

$535.60

Mkt. cap

12.50B

Avg. vol.

327.28K

Volume

177.17K

52-wk high

$614.36

52-wk low

$393.60

EPS

-$12.87

Beta

-0.98

Shares outstanding

23.10M

No. of employees

915

Open

$536.82

High

$547.92

Low

$535.60

Mkt. cap

12.50B

Avg. vol.

327.28K

Volume

177.17K

52-wk high

$614.36

52-wk low

$393.60

EPS

-$12.87

Beta

-0.98

Shares outstanding

23.10M

No. of employees

915

Related stocks

SMMT

Summit Therapeutics Inc

$17.60

+2.77%

VKTX

Viking Therapeutics Inc

$34.87

+2.62%

RVMD

Revolution Medicines Inc

$210.02

-0.40%

NBIX

Neurocrine Biosciences, Inc

$155.64

-1.71%

News stories

From web sources and news partners

www.dars.gov.et

1 week ago

Madrigal Pharmaceuticals (MDGL) Declines 1.83% to $533.76 as Consolidation Continues - MA Cross Alert

https://www.dars.gov.et/

1 week ago

MDGL Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Slip - Net Profit Margin

About Madrigal Pharmaceuticals Inc

CEOPaul A. Friedman

Employees915

Founded2011

HeadquartersWest Conshohocken, Pennsylvania, United States

SectorBiotechnology

Websitemadrigalpharma.com

Analyst	Recommendation	Action	Price target	Projected	Date
Edward Nash Canaccord Genuity	Buy	Reiterated	$612.00	+13.1%	08/11/2026
Andy Chen Wolfe Research	Buy	Upgraded	$605.00	+11.8%	08/04/2026
Eliana Merle Barclays	Buy	Maintained	$962.00	+77.8%	08/03/2026
Unknown Analyst B. Riley Securities	Buy	Initiated	$670.00	+23.8%	07/31/2026
Srikripa Devarakonda Truist Financial	Buy	Reiterated	$709.00	+31%	07/31/2026
Andrew Fein H.C. Wainwright	Buy	Reiterated	$620.00	+14.6%	07/31/2026
Jason Zemansky Bank of America Securities	Hold	Reiterated	$543.00	+0.4%	07/30/2026
Ritu Baral TD Cowen	Buy	Maintained	$644.00	+19%	07/30/2026
Sadia Rahman Wells Fargo	Buy	Initiated	$685.00	+26.6%	07/27/2026
Ashwani Verma UBS	Buy	Maintained	$669.00	+23.6%	07/21/2026
Unknown Analyst UBS	Buy	Maintained	$669.00	+23.6%	07/21/2026
Jonathan Wolleben Citizens JMP	Buy	Maintained	$739.00	+36.6%	07/17/2026
Unknown Analyst Jefferies	Buy	Maintained	$600.00	+10.9%	06/30/2026
Yasmeen Rahimi Piper Sandler	Buy	Maintained	$900.00	+66.3%	06/29/2026
Michael DiFiore Evercore ISI	Buy	Maintained	$649.00	+19.9%	05/07/2026
Kaveri Pohlman Clear Street	Buy	Maintained	$680.00	+25.7%	05/06/2026
Jay Olson Oppenheimer	Buy	Maintained	$650.00	+20.1%	02/09/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	287.27M	321.08M	311.34M	364.25M
Cost of goods sold	18.12M	24.45M	26.85M	40.01M
Cost of revenue	18.12M	24.45M	26.85M	40.01M
Research and development expenses	174.00M	116.27M	108.69M	91.18M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	209.12M	239.98M	268.52M	289.38M
Operating expense	383.12M	356.24M	377.21M	380.55M
Total operating expenses	401.24M	380.69M	404.06M	420.56M
Operating income	-113.98M	-59.61M	-92.72M	-56.31M
Other non operating income	-293.00K	-128.00K	-	-
EBT including unusual items	-114.19M	-58.58M	-94.39M	-57.94M
EBT excluding unusual items	-111.41M	-58.58M	-94.39M	-57.94M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-114.19M	-58.58M	-94.39M	-57.94M
Net profit margin	-39.75%	-18.24%	-30.32%	-15.91%
Earnings per share	-4.96	-2.57	-1.38	-1.99
Interest and investment income	10.31M	9.46M	8.24M	7.10M
Interest expense	-7.45M	-8.30M	-7.82M	-7.94M
Net interest expenses	2.86M	1.16M	424.00K	-836.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	-113.62M	-59.22M	-92.34M	-55.93M
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything